Abstract
Treatment beyond progression with ICIs in patients with HCC is safe and may benefit a subset of patients due to later-onset tumor responses or disease stability. These findings may guide the design of trials testing ICIs in HCC and the use of treatment beyond progression in routine practice.
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have